MA35173B1 - Anticorps anti-cxcr4 ayant des fonctions effectrices et son utilisation pour le traitement du cancer - Google Patents

Anticorps anti-cxcr4 ayant des fonctions effectrices et son utilisation pour le traitement du cancer

Info

Publication number
MA35173B1
MA35173B1 MA36547A MA36547A MA35173B1 MA 35173 B1 MA35173 B1 MA 35173B1 MA 36547 A MA36547 A MA 36547A MA 36547 A MA36547 A MA 36547A MA 35173 B1 MA35173 B1 MA 35173B1
Authority
MA
Morocco
Prior art keywords
effector functions
cancer
treatment
cxcr4 antibody
cxcr4
Prior art date
Application number
MA36547A
Other languages
English (en)
Inventor
Christine Klinguer-Hamour
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA35173B1 publication Critical patent/MA35173B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne une méthode de traitement du cancer par l'administration d'un anticorps monoclonal anti-cxcr4 apte à induire une ou plusieurs fonctions effectrices.
MA36547A 2011-06-20 2013-12-10 Anticorps anti-cxcr4 ayant des fonctions effectrices et son utilisation pour le traitement du cancer MA35173B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11305773 2011-06-20
PCT/EP2012/061893 WO2012175576A1 (fr) 2011-06-20 2012-06-20 Anticorps anti-cxcr4 ayant des fonctions effectrices et son utilisation pour le traitement du cancer

Publications (1)

Publication Number Publication Date
MA35173B1 true MA35173B1 (fr) 2014-06-02

Family

ID=44718440

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36547A MA35173B1 (fr) 2011-06-20 2013-12-10 Anticorps anti-cxcr4 ayant des fonctions effectrices et son utilisation pour le traitement du cancer

Country Status (13)

Country Link
US (1) US20140120555A1 (fr)
EP (1) EP2721069A1 (fr)
JP (1) JP6223966B2 (fr)
KR (1) KR20140041698A (fr)
CN (1) CN103649120A (fr)
AR (1) AR086984A1 (fr)
AU (1) AU2012274104B2 (fr)
BR (1) BR112013032456A2 (fr)
CA (1) CA2838484A1 (fr)
MA (1) MA35173B1 (fr)
MX (1) MX2013015061A (fr)
RU (1) RU2013158624A (fr)
WO (1) WO2012175576A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101809072B1 (ko) * 2013-08-02 2017-12-14 화이자 인코포레이티드 항-cxcr4 항체 및 항체-약물 접합체
TW201718851A (zh) * 2015-09-18 2017-06-01 通用醫院公司 具有抗化學排斥(anti-fugetactic)性質之經修飾自然殺手細胞及其用途
US20180273897A1 (en) * 2015-09-18 2018-09-27 The General Hospital Corporation Modified t-cells having anti-fugetactic properties and uses thereof
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
EP3765519B1 (fr) * 2018-03-13 2024-01-17 Fundación para la Investigación Biomédica del Hospital Universitario la Paz Anticorps anti-cxcr4 combiné à des cellules tueuses naturelles activées et développées pour une immunothérapie anticancéreuse
WO2019191133A1 (fr) 2018-03-27 2019-10-03 Bristol-Myers Squibb Company Surveillance en temps réel de la concentration de protéines à l'aide d'un signal ultraviolet
WO2020172658A1 (fr) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Procédés d'isolement d'une protéine
CN114245869A (zh) 2019-05-23 2022-03-25 百时美施贵宝公司 监测细胞培养基的方法
US20230374064A1 (en) 2020-10-05 2023-11-23 Bristol-Myers Squibb Company Methods for concentrating proteins
WO2023173011A1 (fr) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Expression transitoire de protéines thérapeutiques

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0463151B1 (fr) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation d'anticorps xenogeniques
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
CA2219361C (fr) 1995-04-27 2012-02-28 Abgenix, Inc. Anticorps humains derives d'une xenosouris immunisee
WO1996034096A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1500329B1 (fr) 1996-12-03 2012-03-21 Amgen Fremont Inc. Les anticorps humains qui lient en particulier l'alpha de TNF humain
US7227002B1 (en) 1997-04-14 2007-06-05 Micromet Ag Human antibodies that bind human 17-A1/EpCAM tumor antigen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ES2571230T3 (es) * 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
KR100988949B1 (ko) * 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
WO2007011041A1 (fr) 2005-07-22 2007-01-25 Kyowa Hakko Kogyo Co., Ltd. Composition d'anticorps génétiquement modifié
EP1878747A1 (fr) 2006-07-11 2008-01-16 greenovation Biotech GmbH Anticorps glyco-modifiés
BRPI0718197A2 (pt) * 2006-10-02 2014-09-30 Medarex Inc Anticorpo monoclonal isolado, ou uma porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, e, métodos para preparar um anticorpo anti-cxcr4, para modular a atividade do cxcr4 em uma célula, e para estimular a mobilização de células tronco cd34+ da medula óssea para o sangue periférico em um indivíduo.
JP2011520885A (ja) * 2008-05-14 2011-07-21 イーライ リリー アンド カンパニー 抗ｃｘｃｒ４抗体
EP2172485A1 (fr) * 2008-10-01 2010-04-07 Pierre Fabre Medicament Nouveaux anticorps anti CXCR4 et leur utilisation dans le traitement contre le cancer
EP2246364A1 (fr) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anticorps anti CXCR4 pour le traitement du VIH
EP2371863A1 (fr) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Anticorps humanisé anti CXCR4 pour le traitement du cancer

Also Published As

Publication number Publication date
RU2013158624A (ru) 2015-07-27
EP2721069A1 (fr) 2014-04-23
CN103649120A (zh) 2014-03-19
AU2012274104A1 (en) 2014-01-09
KR20140041698A (ko) 2014-04-04
NZ618655A (en) 2015-09-25
BR112013032456A2 (pt) 2016-11-22
MX2013015061A (es) 2014-07-30
AU2012274104B2 (en) 2017-06-15
JP2014525899A (ja) 2014-10-02
US20140120555A1 (en) 2014-05-01
WO2012175576A1 (fr) 2012-12-27
JP6223966B2 (ja) 2017-11-01
CA2838484A1 (fr) 2012-12-27
AR086984A1 (es) 2014-02-05

Similar Documents

Publication Publication Date Title
MA35173B1 (fr) Anticorps anti-cxcr4 ayant des fonctions effectrices et son utilisation pour le traitement du cancer
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
MA44659B1 (fr) Anticorps anti-tim-3 et compositions
EA201790305A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE
MA35180B1 (fr) Utilisation d4un anticorps immunoconjugue de maytansinoide anti-cd19 pour le traitement de symptomes de malignites a lymphocytes b
MA34647B1 (fr) Procedes de traitement de la polyarthriterhumatoide en utilisant des antagonistes dil-17
EA201490957A1 (ru) Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела
MA33469B1 (fr) Polythérapie à base d'un anticorps afucosylé anti-cd20 et de bendamustine
CO6620013A2 (es) Anticuerpos hacia gdf8 humano
MA35210B1 (fr) Polythérapie comportant un inhibiteur de cdk4/6 et un inhibiteur de pi3k à utiliser dans le traitement du cancer
MA33757B1 (fr) Protéines de liaison à l'antigène de l'il-23 humaine
MA38986B1 (fr) Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate
MA34059B1 (fr) Thérapie anti-angiogénique pour le traitement du cancer des ovaires
UA118255C2 (uk) Композиція, яка містить антитіло до cd38 і леналідомід
MA44645B1 (fr) Traitement combiné d'un anticorps anti-cd20 avec un inhibiteur de bcl-2 et un inhibiteur de mdm2
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
MA46459B1 (fr) Méthode de traitement de lésions rénales aiguës
MA38161A1 (fr) Anticorps anti-bmp-6
MX2020009879A (es) Anticuerpos anti-il-27 y sus usos.
EA201490180A1 (ru) Антитела к erbb3 в комбинации с паклитакселом для лечения гинекологических злокачественных заболеваний
MX2021006980A (es) Anticuerpos anti-il-27 y usos de estos.
EA201891529A1 (ru) Композиции и способы обнаружения и лечения рака яичников
EA202090944A1 (ru) Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
TR201910330T4 (tr) Anti-fosfolin d4 antikoru içeren ilaç.
MA37475A1 (fr) Biomarqueurs pour thérapie par inhibiteur de iap